LXEO (Lexeo) Earnings per share increase in current year
Annual EPS variability demonstrates the profitability dynamics of Lexeo Therapeutics (LXEO), where the figure is recorded at 36.30. Lexeo Therapeutics is developing a unique gene therapy environment for the treatment of rare heart and brain pathologies. Simultaneously, the company is implementing ESG standards for bio-waste disposal, while strictly controlled express channels ensure the rapid delivery of critical genetic vectors.
Analytical breakdowns and data insights for company Lexeo Therapeutics, Inc. (LXEO)
- share price and expert price forecast:
- business market valuation indicators:
- business book valuation details:
- debt burden and liquidity indicators:
Total Debt to Capital Lexeo Therapeutics|LXEO - Long-Term Debt to Equity|Current Liabilities to Equity Lexeo Therapeutics Inc.|LXEO - Company Aggregate Debts|Debts to Book Value Lexeo Therapeutics Inc.|LXEO - Company Long-Term Liabilities|Company Short-Term Debts Lexeo Therapeutics|Intermediate Liquidity Ratio lexeotx.com
- company profitability and valuation multiples indicators:
LXEO - Net Profit|Company Profit Forecast Lexeo Therapeutics|LXEO - P/E Multiple|Projected Price to Earnings Lexeo|LXEO - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Lexeo Therapeutics, Inc.|LXEO - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Lexeo Therapeutics|LXEO - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months lexeotx.com|LXEO - Earnings growth in current year|Expected net earnings per share growth next year Lexeo Therapeutics
- revenue and sales proceeds data:
Fundamental valuation:LXEO Lexeo Therapeutics, Inc.
To minimize fundamental risks, investors should select assets with sustainable positive earnings per share (EPS) growth. This relative annual growth in net income per share measures the percentage change in earnings, reflecting cost management efficiency and actual business income. For Lexeo Therapeutics (LXEO), this indicator is critical, as geopolitical isolation and logistical barriers in gene therapy directly limit profit scalability.
Key competitors
Tempus AI, Inc (TEM) - Earnings growth in current year|Earnings per share growth in current year Qiagen|IONS: Earnings per share increase in current year|Net earnings per share growth this year RGEN (Repligen)|Expected net earnings per share growth this year Avidity Biosciences Inc|Earnings growth in current year CRSP (crisprtx.com)|WGS: Earnings per share growth this year|RARE: Net earnings per share growth this year|Earnings per share trend in current year BEAM|Sarepta (SRPT) - Earnings per share growth in current year|TWST - Expected net earnings per share growth this year|Earnings per share growth in current year 10x Genomics, Inc.|NTLA: Earnings per share increase in current year|Net earnings per share growth this year STOK (Stoke Corp)|Expected net earnings per share growth this year biolifesolutions.com|Earnings growth in current year WVE (Wave Life Sciences Ltd)|Expected net earnings per share growth this year Maze Therapeutics (MAZE)|SION: Net earnings per share growth this year|Expected net earnings per share growth this year Prime Medicine Bio PRME|TSHA: Earnings growth in current year|Earnings per share growth this year QURE|Net earnings per share growth this year MGTX|Earnings per share growth this year RGNX (REGENXBIO)|Earnings growth in current year SLDB|OCGN - Earnings per share growth rate in current year|Earnings per share growth in current year Pacific Biosciences of California PACB|BNTC: Earnings per share growth this year|DSGN - Earnings per share growth in current year|RCKT: Earnings per share growth in current year|FDMT - Net earnings per one share growth for the current year|Korro Bio, Inc (KRRO) - Earnings growth in current year|EDIT (editasmedicine.com) - Earnings growth in current year|Earnings per share growth this year SLN (silence-therapeutics.com)|Earnings per share growth in current year proqr.com (PRQR)|Codexis - Earnings per share growth this year|Earnings growth in current year SGMO (Sangamo Therapeutics)|Earnings growth in current year nautilus.bio NAUT|Metagenomi Inc. - Earnings growth in current year|DTIL (Precision BioSciences Inc.) - Earnings per share growth this year|GBIO: Earnings growth in current year|Earnings per share growth rate in current year Boundless Bio, Inc (BOLD)|XCUR (Exicure) - Earnings growth in current year|Net earnings per share growth this year Imunon (IMNN)|Earnings growth in current year PHIO|Mustang Bio - Earnings per share growth this year|TransCode Therapeutics, Inc. - Net earnings per share growth this year|Expected net earnings per share growth this year Bionano Genomics, Inc. (BNGO)|APDN - Earnings per share growth in current year|Earnings per share increase in current year BLUE (Bluebird Bio)|ImmunoPrecise (IPA) - Earnings per share growth in current year|OMGA: Net earnings per one share growth for the current year|Earnings per share growth in current year Singular Genomics Systems, Inc.|Earnings growth in current year Regulus Therapeutics, Inc.|Net earnings per share growth this year SYRS (Syros)|TBIO - Earnings per share growth rate in current year|Earnings per share growth in current year TRACON Pharmaceuticals, Inc. TCON|Unity Biotechnology (UBX) - Earnings per share growth rate in current year
